Abstract 4143: Enhancing adaptive immune responses with telomerase-mediated telomere targeting therapeutics in hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4143
Abstract: Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver and is the third leading cause of cancer-related deaths. In recent years, immune checkpoint inhibitors (ICIs) have improved treatment of solid tumors… read more here.
Keywords: mediated telomere; hepatocellular carcinoma; telomere targeting; telomerase mediated ... See more keywords
Abstract CT050: A phase 2, multi-center, open-label, dose-finding study evaluating telomere targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct050
Abstract: Background: The modified nucleoside 6-thio-2'-deoxyguanosine (THIO) is a first-in-class direct telomere-targeting agent that is preferentially incorporated in telomeres of telomerase-positive cells, leading to telomere uncapping and cancer cell death. Preclinical evidence indicates that THIO pretreatment… read more here.
Keywords: telomere targeting; targeting agent; patients advanced; thio ... See more keywords
Tumor microenvironment remodeling with a telomere-targeting agent and its cooperative antitumor effects with a nanovaccine
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Nanobiotechnology"
DOI: 10.1186/s12951-025-03471-2
Abstract: The nucleoside analogue 6-thio-2'-deoxyguanosine (6-thio-dG, also known as THIO) is a telomere-targeting agent with important clinical potency. It can selectively kill telomerase-positive tumor cells. We previously reported that THIO could successfully induce immunogenic cell death… read more here.
Keywords: thio; tumor microenvironment; telomere targeting; tumor ... See more keywords
A phase 2, multicenter, open-label, dose-optimization study evaluating telomere-targeting agent THIO sequenced with cemiplimab in patients with advanced NSCLC: Updated results.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.8601
Abstract: 8601 Background: Despite recent approvals for the first-line (1L) treatment of advanced non-small-cell lung cancer (NSCLC), long-term prognosis remains poor with a 5-year survival rate of 28% and limited options exist in patients (pts) refractory… read more here.
Keywords: dose; optimization study; telomere targeting; targeting agent ... See more keywords
Telomere Targeting Approaches in Cancer: Beyond Length Maintenance
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23073784
Abstract: Telomeres are crucial structures that preserve genome stability. Their progressive erosion over numerous DNA duplications determines the senescence of cells and organisms. As telomere length homeostasis is critical for cancer development, nowadays, telomere maintenance mechanisms… read more here.
Keywords: targeting approaches; telomere targeting; maintenance; approaches cancer ... See more keywords